Evidence map›Paper›PMID 31581792›Full record

ArticleCirculation2019

Cardiomyocyte Homeodomain-Interacting Protein Kinase 2 Maintains Basal Cardiac Function via Extracellular Signal-Regulated Kinase Signaling.

Yuanjun Guo, Jennifer Y Sui, Kyungsoo Kim, Zhentao Zhang, Xiaoyan A Qu, Young-Jae Nam, Robert N Willette, Joey V Barnett, Bjorn C Knollmann, Thomas Force and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Circulation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Inactivation of HIPK2 attenuates KRASJournal of experimental & clinical cancer research : CR · 2024
    Article
  8. Review
  9. Small Molecule Allosteric Inhibitor of HIPK2 as a Novel Therapy against Kidney Fibrosis.Journal of the American Society of Nephrology : JASN · 2024
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Yuanjun GuoDivision of Cardiovascular Medicine (Y.G., J.Y.S., Z.Z., Y.-J.N., T.F., H.L.), Vanderbilt University Medical Center, Nashville, TN.
Jennifer Y SuiDivision of Cardiovascular Medicine (Y.G., J.Y.S., Z.Z., Y.-J.N., T.F., H.L.), Vanderbilt University Medical Center, Nashville, TN.
Kyungsoo KimDivision of Clinical Pharmacology (K.K., B.C.K.), Vanderbilt University Medical Center, Nashville, TN.
Zhentao ZhangDivision of Cardiovascular Medicine (Y.G., J.Y.S., Z.Z., Y.-J.N., T.F., H.L.), Vanderbilt University Medical Center, Nashville, TN.
Xiaoyan A QuPAREXEL International, Research Triangle Park, Durham, NC (X.A.Q.).
Young-Jae NamDivision of Cardiovascular Medicine (Y.G., J.Y.S., Z.Z., Y.-J.N., T.F., H.L.), Vanderbilt University Medical Center, Nashville, TN.
Robert N WilletteHeart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapeutic Area GlaxoSmithKline, King of Prussia, PA (R.N.W.).
Joey V BarnettDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN (Y. Guo, J.V.B.).
Bjorn C KnollmannDivision of Clinical Pharmacology (K.K., B.C.K.), Vanderbilt University Medical Center, Nashville, TN.
Thomas ForceDivision of Cardiovascular Medicine (Y.G., J.Y.S., Z.Z., Y.-J.N., T.F., H.L.), Vanderbilt University Medical Center, Nashville, TN.
Hind LalDivision of Cardiovascular Medicine (Y.G., J.Y.S., Z.Z., Y.-J.N., T.F., H.L.), Vanderbilt University Medical Center, Nashville, TN.
Vanderbilt University · USVanderbilt University Medical Center · USGlaxoSmithKline (United Kingdom) · GBPAREXEL International (United Kingdom) · GBUniversity of Alabama at Birmingham · US

Funding

Toward a Mechanism-Based Approach to Treating Cardiac ArrhythmiaR35HL144980 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KNOLLMANN, BJORN C · 2019 to 2025
$7.1M
Signaling Mechanisms Governing Myocardial Fibrosis in Diseased HeartR01HL133290 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Hind Lal · 2017 to 2026
$3.6M
Project-002R01HL143074 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Hind Lal · 2019 to 2026
$3.4M
Heart Failure in Cancer PatientsR01HL119234 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LAL, HIND · 2014 to 2017
$1.6M
NHLBI NIH HHS R01 HL119234NHLBI NIH HHS R01 HL133290NHLBI NIH HHS R01 HL143074NHLBI NIH HHS R35 HL144980
6 · The paper itself

Abstract

backgroundCardiac kinases play a critical role in the development of heart failure, and represent potential tractable therapeutic targets. However, only a very small fraction of the cardiac kinome has been investigated. To identify novel cardiac kinases involved in heart failure, we used an integrated transcriptomics and bioinformatics analysis and identified Homeodomain-Interacting Protein Kinase 2 (HIPK2) as a novel candidate kinase. The role of HIPK2 in cardiac biology is unknown.

methodsWe used the Expression2Kinase algorithm for the screening of kinase targets. To determine the role of HIPK2 in the heart, we generated cardiomyocyte (CM)-specific HIPK2 knockout and heterozygous mice. Heart function was examined by echocardiography, and related cellular and molecular mechanisms were examined. Adeno-associated virus serotype 9 carrying cardiac-specific constitutively active MEK1 (TnT-MEK1-CA) was administrated to rescue cardiac dysfunction in CM-HIPK2 knockout mice.

resultsTo our knowledge, this is the first study to define the role of HIPK2 in cardiac biology. Using multiple HIPK2 loss-of-function mouse models, we demonstrated that reduction of HIPK2 in CMs leads to cardiac dysfunction, suggesting a causal role in heart failure. It is important to note that cardiac dysfunction in HIPK2 knockout mice developed with advancing age, but not during development. In addition, CM-HIPK2 knockout mice and CM-HIPK2 heterozygous mice exhibited a gene dose-response relationship of CM-HIPK2 on heart function. HIPK2 expression in the heart was significantly reduced in human end-stage ischemic cardiomyopathy in comparison to nonfailing myocardium, suggesting a clinical relevance of HIPK2 in cardiac biology. In vitro studies with neonatal rat ventricular CMscorroborated the in vivo findings. Specifically, adenovirus-mediated overexpression of HIPK2 suppressed the expression of heart failure markers,

conclusionsTaken together, these findings suggest that CM-HIPK2 is required to maintain normal cardiac function via extracellular signal-regulated kinase signaling.

Indexed as

AlgorithmsGene Expression ProfilingMAP Kinase Signaling SystemOligonucleotide Array Sequence AnalysisAnimalsBiomarkersHeart FailureMAP Kinase Kinase 1MiceMice, KnockoutMyocardiumProtein Serine-Threonine KinasesBiomarkersHipk2 protein, mouseMap2k1 protein, mouseMAP Kinase Kinase 1Protein Serine-Threonine Kinasesheart failureHIPK2 protein, mouseMAP kinase signaling system

Identifiers

PMID31581792
PMCPMC7219521
OpenAlexW2978235099

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.